Did the company meet or miss consensus revenue and earnings per share estimates for the quarter? | INBX (Aug 13, 2025) | Candlesense
INBX

Did the company meet or miss consensus revenue and earnings per share estimates for the quarter?

Answer

The Inhibrx press‑release does not disclose the company’s actual revenue or earnings‑per‑share (EPS) numbers, nor does it compare them to the Wall‑Street consensus estimates for the quarter. Because the release only announces that the second‑quarter results have been filed and references the completion of the INBRX‑101 transaction, we cannot tell from the provided information whether Inhibrx met, beat, or missed the consensus revenue and EPS forecasts.

Trading implications

  • If the results beat consensus – the stock would likely see upside pressure on the news, especially given the added upside from the INBRX‑101 sale. A bullish play (e.g., buying on any pull‑back or taking a short‑term long position) could be justified, with a focus on the next technical resistance level (around the recent high of $12‑$13) and a stop just below the prior swing low (~$9.50).

  • If the results miss consensus – the market would likely price in a downside, and a short‑bias or defensive positioning would be more appropriate. Traders could look for a break below the 2‑month low (~$8.80) as a trigger for a short entry, with a stop placed above the prior swing high.

What to do now

Until the actual financial details (revenue, EPS, and the analyst consensus figures) are released—either in the SEC filing or in the subsequent analyst commentary—most market participants will remain on the sidelines. The prudent approach is to monitor:

  1. SEC filing (Form 10‑Q) for the exact quarterly numbers.
  2. Post‑release analyst updates for any revisions to consensus estimates.
  3. Pre‑market price action on the day of the filing, which will give the first clue about whether the results are viewed as a beat or a miss.

If the numbers come out and show a clear beat, consider a long position with a modest risk‑to‑reward target (e.g., 15–20% upside). If they fall short, a short or hedged position may be warranted, especially if the price breaks below the short‑term support zone. Until those data points are available, it is best to hold off on any directional trade.

Other Questions About This News

How does Inhibrx's Q2 2025 cash burn rate compare to prior quarters and to industry peers? How did the sale of INBRX-101 affect Inhibrx's revenue and profitability for Q2 2025? What is the expected impact of the 101 Transaction on the company’s cash position and balance sheet? What guidance did Inhibrx provide for the remainder of 2025 and FY2025, and how does it compare to previous guidance? What is the market’s reaction to the announcement (stock price movement, volume) and is there any abnormal trading activity? Are there any new pipeline milestones, clinical data releases, or regulatory updates mentioned that could affect future revenue? What are the terms of the INBRX-101 transaction (valuation, earn‑outs, royalties) and how might they affect future earnings? How does the company's current valuation (EV/EBITDA, P/E) compare with other biotech companies with similar pipelines? What is the outlook for the remaining INBRX product candidates and their potential impact on revenue growth? Are there any risks or uncertainties disclosed in the filing that could affect future performance (e.g., litigation, regulatory delays)? What is the analyst consensus and target price revision, if any, following this earnings release?